Prilenia Therapeutics

Prilenia Therapeutics

Edit info

  • Founded: 2018
  • Location: Herzliya  , Israel
  • Employee range: 11 - 50
  • Clinical stage: Clin3
  • Therapy area: Huntington's disease
  • Drug types: NEU, OPH, GEN, PED
  • Lead product: Pridopidine
  • Funding: $10M B Apr 2022; $62.5M A Jun 2020; ($84.5M total Jun 2020)
  • Investors: Forbion, Morningside Venture Investments, Sectoral Asset Management


prilenia.com

linkedin.com

job board


Business:

Treatments for neurodegenerative and neurodevelopmental disorders

Drug notes:

Also Clin2 ALS, Clin0 Rett syndrome, Clin0 Fragile X, Clin0 neurodegenerative eye disease, Clin0 Parkinson's, Clin0 undisclosed

About:

Prilenia Therapeutics is developing new treatments for neurodegenerative diseases and neurodevelopmental disorders. Prilenia’s lead candidate, Pridopidine, is an oral, highly selective and potent sigma-1 receptor (S1R) agonist currently in late-stage clinical development for amyotrophic lateral sclerosis and Huntington’s disease. S1R is broadly expressed in the brain and central nervous system and regulates several cellular mechanisms impaired in neurodegenerative diseases. By activating S1R, pridopidine can enhance the clearance of toxic proteins and reduce cellular stress and inflammation. Prilenia is expanding the applications of pridopidine through further clinical and preclinical studies.

Prilenia Therapeutics
Director/Senior Director Global Program Safety Phy...
Europe United States / Israel|9 days ago
Apply


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com